Detalhe da pesquisa
1.
Real-world challenges in the diagnosis of primary progressive multiple sclerosis.
Eur J Neurol
; 30(12): 3799-3808, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37578087
2.
Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment.
Mult Scler
; 26(14): 1962-1964, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32406801
3.
Reasons Patients With Primary Progressive Multiple Sclerosis Contact Their Specialist Nurses.
Int J MS Care
; 26(1): 30-35, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38213677
4.
Ocrelizumab associates with reduced cerebrospinal fluid B and CD20dim CD4+ T cells in primary progressive multiple sclerosis.
Brain Commun
; 6(1): fcae021, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38385000
5.
Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis.
Front Neurol
; 14: 1277477, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38020591
6.
Distinct Effector Programs of Brain-Homing CD8+ T Cells in Multiple Sclerosis.
Cells
; 11(10)2022 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35626671
7.
Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib.
JCI Insight
; 7(16)2022 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35852869
8.
Brain-homing CD4+ T cells display glucocorticoid-resistant features in MS.
Neurol Neuroimmunol Neuroinflamm
; 7(6)2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33037101
9.
CT within 6 hours of headache onset to rule out subarachnoid hemorrhage in nonacademic hospitals.
Neurology
; 84(19): 1927-32, 2015 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-25862794